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SHORT COMMUNICATION
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Smnmarv A significant correlation (r=-0.48) was found betw-een the loganrthm of the S-phase fraction of the
pnmarn tumour (SPF) and the logan'thm of the doubling time of lung metastases (T). The estimated median
cell loss factor wxas 880o (range 35-990O).
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It is well known that tumour growth rate is important for the
outcome of cancer patients (Joseph et al., 1971: Mattson and
Holsti. 1980: Spratt and Spratt. 1964). During the last two
decades proliferation measurements from tumour material
has repeatedly been shown to be of prognostic value in
several human cancers (Hall and Levison. 1992). Theoreti-
cally tumour growth rate is determined bv the following
factors: the S-phase fraction (SPF). the duration of the S-
phase (Ts) and the cell loss factor (CLF) (Steel. 1967). Of
these factors only SPF can be determined from tumour
samples without the use of preoperative tumour labelling.
Despite the large literature on the prognostic value of
proliferation measurements. the correlation between prolif-
eration assessment from tumour material and actual tumour
growth in individual cases has never been investigated. It
would be of great value in clinical oncology to be able to
estimate growth of metastases from proliferation measure-
ments on primary tumour material. Tumour growth rate
varies considerably even between tumours of similar histology
(BlomqVist et al.. 1993). and it is obVious that the need for
aggressive anti-neoplastic treatment is dictated bv the
expected clinical course of the disease without active
treatment. In most cases calculation of tumour growth rate
is not practical in patients owing to lack of follow-up.
intervenIng therapeutic measures or poor measurability of
tumour lesions.
A patient with tumour material available for proliferation
measurements and clinically measurable lung metastases
enabled us to investigate whether SPF determined by flow-
cvtometr can be used to estimate the grow-th of subsequent
lung metastases.
Materials and methods
Previouslv wse included patients with lung metastases in a
studv on growth rate on chest radiographs. A minimum time
of 14 davs between tw-o successive measurements was
required. The growth of the lung metastases was calculated
from serial bi-dimensional measurements from chest radio-
graphs. Details. including reproducibilitv of the measure-
ments. have been published previously (Blomqvist et al..
1993). Between 1985 and 1993. 25 patients with seriallv
measurable lung metastases from bone or soft-tissue
sarcomas and tumour material from the primary tumours
available for DNA measurements were found. The total
number of measured metastases was 62. In patients with
several measurable metastases we used the geometric mean of
T. No patients received chemotherapy or radiation during
the time of the study.
From formalin-fixed paraffin-embeedded tissue samples
100 gim sections were cut with a microtome and an adjacent
5 jim slice for light microscopy. This slide was investigated to
study the representativeness of the sample and estimate the
proportion of tumour cells. In 21 cases more than 75% of the
histological slide consisted of tumour cells. in three it was
50-75% cases (all non-diploid) and in one diploid case 25-
50%. The methodology of SPF determination and its
reproducibility has been published previously (Heiden et al..
1990. 1991).




T.=,-Ts [SPF x (1-CLF)]





Where T, clinical tumour doubling time: Tpot potential
doubling time: CLF. cell loss factor: i.. a constant reflecting
the distribution of cells in different phases of the cell cycle
(estimated to be about 0.75) (Steel. 1967): SPF. S-phase
fraction and Ts. duration of SPF.
This means that theoretically there should be a negative
linear correlation between log (T2) and log (SPF) provided Ts
and CLF are independent of SPF. The slope of the regression
line between log T. and log SPF should be equal to - 1.
provided log ['Ts (1 - CLF)] is uncorrelated to SPF. This is
the case when Ts and CLF are independent of SPF.
Moreover:
CLF = 1- [.Ts (SPF x T2)] (5)
Thus. under the assumption of the independence of Ts and
SPF a rough estimate of CLF can be made by inserting an
average value of Ts into formula (5). A value of 12 h for Ts
was used in this study for the estimate of CLF. By using the
same value for Ts in formula (2) T., can be estimated.
Furthermore. (3) can be rearranged as T, x SPF AT5
(1-CLF). By inserting the geometric mean of T- and SPF
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into this formula one obtains a value for the factor xTs/
(1-CLF), which can be used to estimate T2 from SPF
according to the formula T2=(.Ts/l-CLF)/SPF.
Linear regression of log (T2) on log (SPF) and statistical
testing of the correlation coefficient were done by the least
squares method with the Statistica software on a Macintosh
computer. The statistical significance ofdifferences in SPF, T2
and CLF between diploid and non-diploid tumours was
tested by the Mann-Whitney test.
Results
Patient and tumour characteristics, SPF, ploidy, T2 values,
estimated cell loss factor and Tpo, are shown in Table I. Nine
patients had diploid tumours and 16 non-diploid tumours.
Median SPF and T2 were 9.8% (range 1.6-19.7) and 32
days (range 6.9-1172) respectively. The geometric means
were 9.3% and 36 days respectively. Median SPF was 8.4%
in diploid tumours and 10.2% in non-diploid tumours
(P=0.29). Median T2 was 32 days in diploid and 34 days
in non-diploid tumours (P=0.77). Median estimated Tpot was
3.8 days (range 1.9-23.4). The median estimated cell loss
factors for all patients were 88% (range 35 -99%). The
median CLF was 86% in diploid and 90% in non-diploid
tumours (P =0.39).
A scattergram of log(SPF) and log(T2) is shown in Figure
1. There was a statistically significant negative linear
correlation (r=0.48, P=0.02) between log(SPF) and log(T2)
with a fitted regression equation of log(T2) = -0.83
(logSPF) + 2.35. The correlation between log(SPF) and
log(T2) was significant in the diploid cases alone (r= -0.76,
P=0.02), but statistically non-significant (r = -0.34, P =0.20)
in non-diploid cases. The estimated regression coefficients
were however similar in the diploid [log(T2)=
-0.92 x[og(SPF)]+ 2.34] and non-diploid [log(T2) =-0.90
x [log(SPF)J + 2.48] cases.
Discwsfio
A significant correlation between high SPF values and poor
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Figie 1 Correlation between the logarithm of the S-phase
fraction (SPF) and log doubling time (T2) in diploid and non-
diploid sarcomas. Diploid tumours (0); non-diploid tumours
(0). The thin line is the regression line for non-diploid cases and
the thick line the regression line for diploid cases.
including breast cancer, gastrointestinal and haematological
malignancies (Hall and Levison, 1992). We have recently
demonstrated a significant correlation between high SPF
values and a poor prognosis also in soft-tissue sarcomas
(Huuhtanen et al., 1995). Although the impact of high SPF
values on cancer prognosis probably stems from its
association with tumour growth rate, there is little data
available comparing clinical tumour growth and proliferation
measurements.
There are several reasons for expecting the correlation
between SPF and tumour growth to be far from perfect.
According to Steel (1967), tumour growth is determined by
SPF as described by the formula (3) T2=A.Ts/[SPF x (1-
CLF)]. Despite lack of knowledge of CLF and Ts in the
present study linear regression on log T2 against log SPF
yielded a fairly good correlation, indicating that SPF can
indeed be used to obtain a rough estimate of T2. The r2 was
Table I Patient and tumour characteristics and tumour kinetic parameters in individual cases
Sex and age Histology Grade Site T2 SPF Tp,0 CLF Ploidy
F67 MFH 4 Calf 6.9 8.4 4.5 35 D
M42 MFH 4 Thigh 9.1 19.7 1.9 79 A
F35 LMS 4 Scapula 10.8 9.3 4.0 62 A
M66 Sarcoma NOS 4 Groin 13.7 11.2 3.3 76 A
M37 Sarcoma NOS 4 Buttock 15.6 7.4 5.1 68 A
F36 Sarcoma Ewing 4 Buttock 15.6 16.9 2.2 86 D
M18 Osteosarcoma 4 Femur 22.6 15.4 2.4 90 A
F63 Sarcoma NOS 4 Foot 26.2 21.7 1.7 93 D M34 Sarcoma Ewing 4 Maxila 27.8 8.9 4.2 85 D
F51 Malignant schwannoma 3 Retroperitoneum 29.2 10.1 3.8 87 A F79 MFH 4 Thigh 30.8 18.0 2.1 93 A M79 MFH 3 Upper arm 31.7 9.8 3.8 88 A
M29 SarcomaNOS 4 Axilla 32.2 6.4 5.9 82 D M54 MFH 4 Thigh 34.9 7.5 5.0 86 D F56 LMS 3 Uterus 36.5 12.2 3.1 92 D F62 LMS 2 Thigh 36.5 16.1 2.3 93 A M61 SarcomaNOS 4 Maxilla 36.6 9.8 3.8 90 A M27 Sarcoma NOS 4 Neck 38.9 3.9 9.6 76 A M56 Osteosarcoma 3 Femur 44.7 8.4 4.5 90 A M21 Osteosarcoma 4 Tibia 49.5 10.2 3.7 93 A F79 Fibrosarcoma 2 Trunk 68.7 16.3 2.3 % A F41 Sarcoma NOS 4 Upper arm 73.6 2.7 13.9 81 D M55 Liposarcoma 3 Shoulder 75.0 10.2 3.7 95 A F68 LMS 2 Retroperitoneum 276 1.6 23.4 92 D M20 Chondrosarcoma 3 Pelvis 1172 6.3 5.9 99 A
F, female; M, male; T2, doubling time (days); SPF, S-phase fraction (%);CLF, cellloss factor (%) estimated as CLF = 1-[;Ts/(SPFT2)]with A
= 0.75,Ts
= 12h;Tpot potentialdoublingtime(days)estimatedasTp,
= ATs/SPFwith,A = 0.75,Ts
= 12h;LMS, leiomyosarcoma;MFH, malignant fibrous histiocytoma;NOS, not otherwise specified; D, diploid; A, non- diploid.SPF/T2 m klng metastases from sarcomas
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Table H Selected studies of labelling index (LI). the duration of the S-phase (Ts) and potential doubling times (Tpo,) in human
tumours
Mfedian
Ts range SPF or LI
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1.3 BRDU in vivo
4.0 IUDR in vivo
4.8 BRDU in ivo
3.9* IUDR in vivo
6.2 BRDU in vivo
15.3 TL in vitro
8.2 BRDU in vivo
5.6 BRDU in vivo
3.9 BRDU in vivo
9.8 BRDU in vivo
13.4 BRDU in vivo
7.3 IUDR in vivo
7.1 BRDU in iio
5.7 BRDU in vivo
5.2 BRDU in uiio
2.0 BRDU in viao
Reference
Sakuma (1980)
Begg et al. (1988)
Wilson et al. (1988)
Begg et al. (1990)
Forster et al. (1992)
Silvestnrni et al. (1974)
Rex-et al. (1992)
Wilson et al. (1988)
Rew et al. (1991)
Riccardi et al. (1988)
Riccardi et al. (1988)
Begg et al. (1988)
Wilson et al. (1988)
Wilson et al. (1988)
Wilson et al. (1988)
Raza et al. (1990)
AML. acute non-lymphocytic leukaemia: BRDU. bromodeoxyunidine: IUDR. iododeoxyurindine: TL. thymidine labellinz: LI.
labelling index: Tp, potential doubling time. *Measured from graph.
only 0.23. indicating that other factors also have a significant
impact on the doubling time. i.e. measurement and sampling
errors. variations in Ts and CLF.
Labelling index (LI. which theoretically should be the
same as SPF). Ts and TP't of human tumours in studies that
have used either radioactive or halogenated nucleotide
analogues are summarised in Table II (Begg et al.. 1990.
1988; Forster et al.. 1992: Raza et al.. 1990: Rew et al.. 1992.
1991: Riccardi et al.. 1988: Sakuma 1980: Silvestrini et al..
1974: Wilson et al.. 1988). The published values ofTp, can be
compared with measured clinical doubling times (Charbit et
al.. 1971) ranging from approximately 1 to 5 months. The
discrepancv between TP, and clinically determined T, is
postulated to be caused by cell loss.
There are no previous published studies in the literature
that attempt to define the extent of cell loss in human
tumours by correlation of proliferation measurements and
clinical doubling times in individual cases. On the basis of
published x-alues of Tp, and T, cell loss in human tumours
has been estimated to be about 60-70% by Steel (1967) and
68-95o0 bv Malaise et al. (1973) in tumours of different
histology. In the study of Malaise et al. (1973) the mean
x-alue of estimated cell loss for 32 mesenchvmal tumours was
6800//. By substituting a plausible x-alue of 12 h for Ts (the
weighted mean of the median Ts for all tumour groups in
Table II) an estimate of the cell loss factor in individual cases
u-vas made in the present study. The cell loss factor varied
from 35°o to 990o with a median of 88%. which is somewhat
larger than the previous estimates (Malaise. et al.. 1973: Steel.
1967). The large cell loss factor indicates that cell death is as
least as important a factor for clinical tumour growth as cell
proliferation.
The estimates of CLF. especiallx in cases with extreme
alues. should be x-ieu-ed with extreme caution hou-ever.
because thev are calculated on the basis of a number of
assumptions. Firstly. there may be differences between the S-
phase x-alues in the primarx tumour and its metastases as well
as xvariation within the primary tumour itself In a previous
study on some of the patients included in this study we found
that the growth rate of multiple metastases in the same
patient x-as remarkably similar (Blomqvist et al.. 1993). This
indicates that the growth rate in different subclones of the
sarcomas in this study seems to be quite constant. One studx
in breast cancer reported relatively stable SPF values in
primarx tumours and metastases (Feichter et al.. 1989).
whereas tu-o studies in ox arian carcinoma both indicated
considerable xvariation in SPF between different samples from
the primary tumour. and between primar- tumours and
metastases in the same patient (Kaeme et al.. 1994:
Kallioniemi 1988). Interestingly. the heterogeneity of SPF
both in breast and ovarian cancer was reported to be larger
in non-diploid tumours (Feichter et al.. 1989: Kaerne et al..
1994).
Secondly. there rmight be a correlation between CLF or
Ts and SPF. There is little data available on this issue. The
slope of the regression line between log (Ta) and log(SPF)
w-as. however. close to the theoretical value of -1. which
should not be the case if either Ts or CLF were strongly
correlated to SPF (for elaboration see Materials and
methods).
Thirdly,. patients with measurable lung metastases might
be a non-random subset of sarcoma patients in general: in
our department only 25 out of more than 200 sarcoma
patients treated during the period of the study fulfilled the
inclusion cnrteria.
An unexpected finding was that the correlation between
SPF and clinical grow-th of metastases was closer in diploid
than in non-diploid tumours. In fact. one would expect the
opposite owing to the inevitable contamination of normal
cells in the SPF estimate in diploid tumours. The difference
might naturally be caused by chance in this relatixvely small
patient sample. The regression equations between T, and SPF
were. however. almost identical in diploid and non-diploid
tumours. but the non-diploid tumours showed much larger
variability. This may indicate that other factors responsible
for T, (i.e. CLF and Ts) than SPF might be more important
determinants of T, in non-diploid tumours. Two prexvious
studies. one of 100 colorectal cancer cases and the other of 47
patients With head and neck carcinomas. have demonstrated
significantly longer Ts times in non-diploid than in diploid
tumours indicating systematic differences in Ts between
diploid and non-diploid tumours (Begg et al.. 1990: Rew et
al.. 1991). Interestingly. in a recent study of the patient
material from xxhich the present patients u-ere recruited SPF
wxas a strong predictor of metastatic dex elopment and
survival in diploid tumours only (Huuhtanen et al.. 1995).
The estimated regression equation can be approximately
reformulated in the form T =300 SPF. enabling a simple
method of estimating the expected tumour doubling time
from SPF in indixidual cases. In non-diploid tumours.
however. this estimate is relatixvelv inexact. since SPF
explained only about 100"o of the xvariability (xvariance) in
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